AzTrials
AzTrials

Heart Failure With Reduced Ejection FractionEDUC-ICNCT05751772

Improving Knowledge in Heart Failure Inpatient With Therapeutic Education

A study testing Patient therapeutic education in people with Heart Failure With Reduced Ejection Fraction and Heart Failure; With Decompensation, run by University Hospital, Geneva at 1 site in Switzerland.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The objective is to evaluate the impact of a pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients. The knowledge score on heart failure disease and medications will be compared between two groups one month after hospitalization. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Patient therapeutic education
Could I receive a placebo?
No, everyone receives an active treatment
How many people
38 participants
Where
1 siteSwitzerland
Study dates
13 Dec 2022to 31 Jan 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Hospitalization in the Department of General Internal Medicine or Cardiology for decompensated heart failure with lowered left ventricular ejection fraction (LVEF) (≤40%) from any cause or mildly lowered LVEF (41-49%) with the presence of heart failure-specific drug therapy
  • Stability of the patient's clinical condition
  • ≥ 2 heart failure medications
  • ≥18 years
  • Full capacity of discernment
  • Absence of cognitive impairment
Show all 9Show fewer
  • Ability to speak, understand and read in French
  • Get a personal telephone
  • Consent form signed by the participant

Who cannot join

  • Inability to follow study procedures
  • Institutionalized persons
  • Asylum seekers, homeless people, prisoners
  • Incapacity of judgment and discernment

Trial locations and contacts

1 site in 1 country.

Switzerland1 site
  • University Hospital of Geneva

    Geneva, 1205

Other trials in Switzerland

About this study

Official title: Disease and Medication Knowledge Improvement: A Swiss Single-center Randomized Controlled Trial With Heart Failure Inpatients

The objective is to evaluate the impact of a pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients. The knowledge score on heart failure disease and medications will be compared between two groups one month after hospitalization. The intervention group will receive a therapeutic education intervention and usual hospital care and the control group will receive only usual hospital care.

Read the detailed description

Heart failure patients are at risk of decompensation of their disease and frequent hospitalizations. Poor adherence to their treatment may be the cause. By improving the knowledge of hospitalized heart failure patients about their disease and their medications, it is expected that these patients will adhere better to their heart failure drug therapy and benefit from a better effectiveness of their treatment. This could promote an improvement in their quality of life, a decrease in their risk of disease complications and even an increase in their life expectancy.

The objective of this research project is to deploy a therapeutic teaching intervention at the bedside of decompensated and hospitalized heart failure patients, associated with follow-up by the pharmacist at discharge from the hospital, and to measure its impact on knowledge change (primary endpoint), on their beliefs about medications, on their therapeutic adherence, and on the consumption of unplanned care such as rehospitalizations and emergency room visits (secondary endpoints).

Being tested
Patient therapeutic education
Keywords
patient therapeutic education, clinical pharmacy, pharmaceutical care
Medical subject headings
Heart Failure, Medication Adherence, Behavior

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Patient therapeutic educationOther

    Also called inpatient therapeutic education interview and outpatient pharmaceutical follow-up

    The pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients is made by a clinical pharmacist and includes:

    1. Targeted education on patient needs related to heart failure, heart failure medications and self-care;
    2. a pre-discharge interview to consolidate key teaching messages and prepare the patient for their discharge treatment plan;
    3. a telephone call the week of discharge to ensure pharmaceutical follow-up between hospital care and return home (continuity of care, transition of care).
Study groups in NCT05751772
Study groupRoleWhat they receive
"Patient therapeutic education" groupExperimentalThe intervention group will benefit from a pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients and usual hospital care (medical and nursing care)
Receives: Other: Patient therapeutic education
"Usual hospital care" groupNo interventionThe control group do only benefit from the usual hospital care (any medical and nursing care giving to an acute heart failure inpatient) and won't benefit from the pharmacist's educational intervention.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in knowledge score

    Patients' level of knowledge about their disease and heart failure medications before the educational pharmaceutical intervention (pre-test) and immediately after the intervention (post-test n° 1) for the intervention group , as well as at 1 month after hospital discharge (post-test n°2) for the intervention and control group. It will be measured by means of a 17-question questionnaire specifically developed for this project. This level is valued by a minimum score of 0 points and a maximum of 17 points. Higher score means a better level of knowledge. The positive difference between pre-test and post-tes means an increase in knowledge and a negative difference means a decrease in knowledge.

    Measured: at the baseline time (zero time), immediately after therapeutic education intervention and 30 days after hospital discharge

Secondary outcomes (9)
  1. Change in Beliefs about medicines Score

    Beliefs about medicines will be measured via the specific Beliefs about Medicines Questionnaire (BMQs) score at baseline time (at the inclusion time)(pretest) and at 1 month after hospital discharge (post-test) in both groups.

    Scores range from 5 to 25 points for both subscales. The higher the score for the specific need, the more it means that the patient has a strong perception that he needs the drugs to be healthy and live. For specific concerns, the higher the score, the more the patient is concerned about a potential negative effect of taking the medication. A third score can be calculated by subtracting specific concerns from specific needs. This gives a score of -20 to +20. A positive value means that the need for the treatment exceeds the concerns of taking it.

    Measured: at the baseline time (zero time),30 days after hospital discharge

  2. Change in Medication Adherence Score

    Adherence will be assessed with the Three Item Self Report Scale at baseline time (at the inclusion time) (pre-test) and at 1 month after hospital discharge (post-test) in both groups.

    This questionnaire consists of 3 questions; one which evaluates the number of days of forgetting to take medication over the last month, one which evaluates the frequency of taking medication according to medical prescription and the third which makes it possible to measure the level of competence in the correct taking of medication that takes ownership of the patient. Responses are converted on a scale of 0 to 100 (0 is the lowest adherence and 100 the highest). An average of the three answers is used to assign the adhesion score. Higher the score is, better the adherence is.

    Measured: at the baseline time (zero time),30 days after hospital discharge

  3. Level of satisfaction on therapeutic education

    Patient satisfaction will be assessed using a 13-questions questionnaire specifically developed for this project, after the education interview to assess the usefulness and quality of the teaching intervention. There is no score related to the questionnaire.

    This qualitative assessment will allow us to determine whether this new intervention should be continued and to identify its strengths and weaknesses.

    Measured: immediately after therapeutic education intervention

  4. Rehospitalization or emergency room visits

    The rate of rehospitalization or emergency room visits will be evaluated during the telephone call made by a research assistant at D30 post hospital discharge. The cause of hospitalization will be determined by means of the computerized hospital patient file if he is rehospitalized at the university hospital of Geneva (HUG) or directly to the patient (or his attending physician depending) if he is hospitalized in another hospital. It is interesting to assess whether the patient consumed unplanned care and whether it was related to instability of his heart failure.

    Measured: 30 days after hospital discharge

  5. Death at 1 month after discharge

    The mortality rate will be assessed in both groups. This information can be collected from the participants' computerized patient records if mentioned or from the participants' relatives or attending physician.

    Measured: 30 days after hospital discharge

  6. Patient experiment and feeling after discharge

    The patient's experience and feelings upon returning home will be assessed during a telephone call between D3 and D7 after the patient's discharge from the hospital with open questions (no validated questionnaire is used). The objective will be to identify the patient's needs, their feelings about going home, what they liked, what they missed to readjust the counseling to the patient.

    Measured: 7 days after hospital discharge

  7. CardioMeds app usability

    Use and usability of the mobile smartphone application (CardioMeds® ) will be explored by the research assistant during the telephone call at D30 post hospital discharge using a validated standardized questionnaire (System Usability Scale = SUS).

    SUS gives a single score representing a measure composite of the general user-friendliness of the studied service.

    The score ranges from 0 to 100.It is generally considered that a score is "good" from 75, fair or fair between 50 and 75. A score below 50 reveals major problems in terms of customer satisfaction.

    Measured: 30 days after hospital discharge

  8. Self-Care of Heart Failure Index

    Self-care skills of patients using CardioMeds® will be explored using a validated score, the Self-Care of Heart Failure Index composed of 22 questions to measure the effect of this application on patients' level of empowerment in their care. The scale is subdivided in three measurement : maintenance score, management score and self-care confidence score. Each scale score is standardized to a 0 to 100 range. A score of ≥70 can be used as the cut-point to judge self-care adequacy,

    Measured: 30 days after hospital discharge

  9. Level of satisfaction on global pharmaceutical care

    This second satisfaction questionnaire consisting of 8 questions specifically developed for this project, will be sent at 1 month after hospital discharge to assess the patient's overall satisfaction with the pharmaceutical care follow-up provided. There is no score related to the questionnaire.

    This qualitative assessment will allow us to determine whether the hospital pharmaceutical care

    Measured: 30 days after hospital discharge

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Mar 2023
  2. Study start13 Dec 2022
  3. Primary completion31 Jan 2024
  4. Study completion31 Jan 2024

Why it stopped: Difficulty in recruiting and lack of resources

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Model description
Single-center randomized controlled trial
Masking
None (open label)
Enrolment
38 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05751772
Sponsor's protocol ID
2022-00731
Acronym
EDUC-IC
Status last verified
Mar 2024
First submitted
4 Nov 2022
Last updated
26 Mar 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Individual participant data (original data sets) that underlie the results reported in published articles, after deidentification (text, tables, figures, and appendices).

Questions about this trial

What is this clinical trial studying?

A study testing Patient therapeutic education in people with Heart Failure With Reduced Ejection Fraction and Heart Failure; With Decompensation, run by University Hospital, Geneva at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 26 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Difficulty in recruiting and lack of resources). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in knowledge score (time frame: at the baseline time (zero time), immediately after therapeutic education intervention and 30 days after hospital discharge). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Mar 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in